| Authors: |
Salama AKS; Duke University, Durham, NC., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA., Macrae ER; Columbus Oncology and Hematology Associates, Columbus, OH., Park JI; Medical College of Wisconsin, Milwaukee, WI., Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton D; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA., Armstrong DK; Johns Hopkins University, Baltimore, MD., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, NCI, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
